web analytics

IRDS: Predictive 7-gene Signature for Breast Cancer Therapy

Published:
Lead Inventor: Ralph Weichselbaum
Print or Save to PDF

SUMMARY

  • After surgical removal of breast cancer tumors, adjuvant chemotherapy and radiation therapy have an absolute survival benefit of just 5-10%. Currently approved breast cancer diagnostics do not predict patient responses to these treatment options, despite the capability of such a diagnostic to avoid unnecessarily exposing patients to toxic side effects.
  • From 52 differentially expressed genes, the investigators found 7 genes that successfully predict patient overall survival in response to chemotherapy or radiation therapy. The 7 genes are IFN stimulated and mediate cellular response to DNA damage.
  • The invention is a signature of 7 genes that can be used to predict breast cancer resistance to DNA damage. Lower resistance to DNA damage pinpoints patients that will benefit from chemotherapy and radiation therapy.
  • The gene signature was validated in a retrospective dataset of 295 early stage breast cancer patients (HR=1.2).

 

FIGURE

Patients who received adjuvant chemotherapy (green, n=110) and those who did not (orange, n=185) were classified using the clinically approved Mammaprint gene signature (NKI 70) as having a good (NKI70 -) or poor (NKI 70+) prognosis. The poor prognosis patients were further stratified with the invention gene signature (IRDS). IRDS (-) patients have increased sensitivity to chemotherapy, evident in comparing the Kaplan-Meier survival curves of the two treatment groups. 

 

ADVANTAGES

ADVANTAGES

  • Clear binary results
  • Prevents unnecessary toxic treatments
  • Assesses breast cancer patients not addressed by available tests.
  • Compatible with conventional diagnostic platforms.
  • Greater than 85% sensitivity and specificity
  •  Useful across breast cancer subtypes

 

APPLICATIONS

  • Precision medicine (Chemotherapy and radiotherapy)
  • Clinical trial enrollment

 

PUBLICATIONS

 

 

  • US: 7,892,740